AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments.
To join in the study, participants must:
* Be 18 years or older
* Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread to other parts of the body
The study will look at:
* Whether PF-08634404 is safe to use with other cancer medicines.
* What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease.
* Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors.
The study has different parts, each testing PF-08634404 with a different cancer medicine:
* Part A will test PF-08634404 with a medicine called sigvotatug vedotin.
* Part B will test PF-08634404 with a medicine called PF-08046054/SGN-PDL1V
Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Start Date30 Jan 2026

Sponsor / Collaborator

Pfizer Inc.

NCT06758401

/ RecruitingPhase 3

AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control.
The study is seeking for participants who:
* Are confirmed to have NSCLC (Stage 3 or 4).
* Have PD-L1 levels in more than 50% of the cancer cells.
All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab.
Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.

Start Date23 Jul 2025

Sponsor / Collaborator

Pfizer Inc.

ChiCTR2600128203

/ RecruitingPhase 3IIT

A randomized, phase 3, open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Start Date01 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Sigvotatug vedotin

100 Translational Medicine associated with Sigvotatug vedotin

100 Patents (Medical) associated with Sigvotatug vedotin

543

Literatures (Medical) associated with Sigvotatug vedotin

02 Oct 2026·MOLECULAR CANCER THERAPEUTICS

An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer

Article

Author: Olson, Devra J. ; Burcher, Maddy ; Moskovitz, Eliana ; Dekker, Joseph D. ; Carosino, Christopher M. ; Levengood, Matthew R. ; Sandall, Sharsti ; Yan, Tianyang ; Duniho, Steve ; Gray, Marlena ; Mikell, Iliyana ; Farr, Lauren ; Ortiz, David J. ; Garcia, Nicolas H. ; Hein, Renee F. ; Mazahreh, Rebecca C. ; Ardalani, Hamidreza

Abstract:

Non–muscle-invasive bladder cancer (NMIBC) accounts for 75% of all new bladder cancer diagnoses. Despite new therapeutic treatment options aiming to replace Bacillus Calmette–Guérin (BCG), the standard of care for 40+ years, high rates of failure and recurrence of disease remain in patients with NMIBC. Integrins are a large family of cell surface receptors involved in key biological processes such as cellular adhesion, motility, and cytokinesis, and integrin β-6 (IB6) has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. IB6 is being actively tested in lung cancer with the antibody–drug conjugate (ADC) sigvotatug vedotin. In this study, we introduce PF-08052667, an IB6-directed ADC that has been optimized for local delivery via intravesical dosing in patients with NMIBC. PF-08052667 leverages the high and consistent expression of IB6 in NMIBC tumors for efficient ADC internalization. In PF-08052667, an average of 8 monomethyl auristatin E molecules are attached to an IB6-specific humanized IgG1 antibody via a glucuronide linker shown to increase potency in vitro. PF-08052667 efficacy was further optimized when administered after a bladder prewash, which improved ADC delivery to the bladder tissue. The combination of highly potent PF-08052667 with bladder prewash demonstrated enhanced in vivo efficacy while maintaining minimal systemic exposure and no systemic toxicity. Together, the results position PF-08052667 as a potential first-in-class ADC optimized for intravesical delivery and support further clinical examination in an ongoing phase I trial testing safety and efficacy in BCG-unresponsive and BCG-exposed NMIBC (NCT07206225).

10 Jun 2026·JOURNAL OF CLINICAL ONCOLOGY

First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer

Article

Author: Bockorny, Bruno ; Hollebecque, Antoine ; Piha-Paul, Sarina A. ; Galvao, Vladimir ; Hernandez-Guerrero, Tatiana ; Patilea-Vrana, Gabriela ; Lopez, Juanita S. ; Dowlati, Afshin ; Wang, Tianhua ; Patnaik, Amita ; Kingsley, Edwin ; Knowles, Scott ; Sehgal, Kartik ; Rivera Herrero, Fernando ; Wang, Yimo ; Perez, Cesar Augusto ; Peters, Solange ; Sanborn, Rachel E. ; Fontana, Elisa ; Li, Jerry ; Calvo, Emiliano

PURPOSE:

Integrin beta-6 (IB6) is highly expressed in non–small cell lung cancer (NSCLC) and other solid tumors and potentially associated with poor outcomes. Sigvotatug vedotin (SV), a novel IB6-directed antibody-drug conjugate, demonstrated acceptable safety and encouraging antitumor activity in dose escalation. We report updated results for dose-expansion regimens in advanced NSCLC (aNSCLC).

METHODS:

SGNB6A-001 is an open-label, multicenter, dose-escalation/dose-expansion phase I study evaluating safety, tolerability, pharmacokinetics (PK), and antitumor activity of SV in patients with select advanced solid tumors. After dose escalation, dose expansion further explored three regimens: 1.25 mg/kg total body weight (TBW) on Days 1 and 8 of a 21-day cycle, 1.5 mg/kg TBW on Days 1 and 15 of a 28-day cycle (once every 2 weeks), and 1.8 mg/kg adjusted ideal body weight (AiBW) once every 2 weeks. Eligible patients had prior chemotherapy and immunotherapy or targeted therapy if indicated. Primary end points were safety and determination of an optimal dosing schedule. Secondary end points were antitumor activity, PK, and immunogenicity.

RESULTS:

As of November 26, 2024, 117 patients with aNSCLC were treated in the above cohorts. Any-grade and grade ≥3 treatment-emergent adverse events occurred in 98% and 48% of all patients, respectively, and in 94% and 35% of patients receiving SV 1.8 mg/kg AiBW once every 2 weeks. Modeling revealed that the AiBW regimen resulted in lower PK variability than TBW regimens. The objective response rate and median duration of response were 19% and 11.3 months in the overall population, respectively, and 29% and 12.8 months in patients with nonsquamous, taxane-naïve NSCLC.

CONCLUSION:

SV demonstrated a manageable safety profile and promising antitumor activity with durable responses in aNSCLC. PK and clinical data support further investigation with the recommended 1.8-mg/kg AiBW once every 2 weeks dosing regimen.

01 Jun 2026·CANCER

Mapping the antibody–drug‐conjugates landscape in non–small cell lung cancer: Where are we and where are we going?

Review

Author: Parisi, Claudia ; Planchard, David ; Barlesi, Fabrice

Abstract:

Antibody–drug conjugates (ADCs) represent a rapidly advancing therapeutic class in the treatment of non‐small cell lung cancer (NSCLC), offering targeted delivery of cytotoxic agents to tumor cells while minimizing off‐target toxicity. In recent years, several ADCs have emerged in both early (phase 1–2) and late (phase 3) clinical development, reflecting a growing recognition of their potential to improve outcomes in defined subsets of patients with advanced NSCLC. Late‐phase ADCs include trastuzumab deruxtecan (targeting HER2 [human epidermal growth factor receptor 2]), datopotamab deruxtecan and sacituzumab govitecan (targeting TROP2 [trophoblast cell‐surface antigen 2]), patritumab deruxtecan (targeting HER3), telisotuzumab vedotin (targeting c‐MET [cellular‐mesenchymal epithelial transition factor]), and sigvotatug vedotin (targeting IB6 [integrin beta‐6]). Research efforts are ongoing to explore novel payloads, linker technologies, and targets to expand the applicability of ADCs across broader NSCLC populations, including those with limited treatment options (e.g., EGFR ‐mutant disease in the context of treatment resistance). Despite their promise, challenges remain in optimizing patient selection, overcoming resistance mechanisms, and managing unique toxicity profiles. Ongoing, biomarker‐driven trials and combination strategies with immunotherapy or tyrosine kinase inhibitors hold the potential to further enhance the efficacy of ADCs. In this review, the authors highlight the current landscape and future directions of ADCs in NSCLC, emphasizing available results for compounds in late‐stage clinical development and different disease settings.

News (Medical) associated with Sigvotatug vedotin

02 Nov 2026

·www.biospace.com

Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict

iStock, rudall30 With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major backbone” of cancer treatment. Summit Therapeutics’ Akeso-partnered PD-1xVEGF bispecific antibody ivonescimab finds itself at the center of a cancer collaboration craze, with some of biopharma’s biggest names lining up for a chance to hook their respective assets onto what could possibly be oncology’s next big thing. After besting Merck’s mega-blockbuster Keytruda in a China-based head-to-head Phase 3 study in non-small cell lung cancer (NSCLC) in September 2024, “ivonescimab pretty much set the world on fire,” Graig Suvannavejh, managing director and senior biotech and biopharma analyst at Mizuho Securities, told BioSpace in an email interview. Keytruda inhibits the PD-1 pathway, which prevents cancer cells from evading and weakening the immune system’s anticancer response. Adding a VEGF mechanism on top of this additionally stops the formation of new blood vessels, starving the tumor. The PD-1xVEGF market could exceed $30 billion by 2032, according to Vision Lifesciences. A telling readout from a global Phase 3 trial testing ivonescimab versus Keytruda as a frontline treatment option for NSCLC is set to drop “any day now,” Suvannavejh noted. “If ivonescimab ultimately lives up to its billing of being better than Keytruda,” he said, the asset “theoretically could stand to become the next major backbone of treatment in cancer in the future.” This notion is not lost on other drugmakers. Many leading biopharma companies have entered into clinical trial collaborations with Summit, hoping to package their products into combo regimens with ivonescimab. “Organizations have increasingly approached us about partnering on clinical studies evaluating ivonescimab in combination regimens,” Dave Gancarz, chief business and strategy officer at Summit, told BioSpace in an email. Other companies with active clinical trial collaborations to pair their drugs with ivonescimab include AstraZeneca and Revolution Medicines. Gancarz said that this activity reflects broad scientific interest in the drug’s potential as an immunotherapy backbone across multiple tumor types and treatment settings. Lung cancer Summit Declares NSCLC Victory Over Keytruda, Analysts Advise Caution With China-Only Data In advanced non-small cell lung cancer, Summit Therapeutics’ ivonescimab appears to be 49% more effective at reducing the risk of disease progression or death versus Merck’s Keytruda in a late-stage study. However, analysts contend the caveat is that the trial was conducted in an entirely Chinese patient population. September 9, 2024 · 2 min read · Tristan Manalac Read more AstraZeneca in particular has bought into Summit and ivonescimab. Not only has the British-Swedish heavyweight struck two separate clinical trial collaborations with the biotech, it recently gave Summit a $2 billion equity investment . “The completed equity investment gives AstraZeneca direct economic participation in Summit’s future value creation across the broader ivonescimab opportunity, not only potential combinations with AstraZeneca medicines,” a company spokesperson told BioSpace in an email. Business Summit snags $2B investment from AstraZeneca, clearing financial overhang The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights. September 29, 2026 · 3 min read · Tristan Manalac Read more Pharma powerhouses and rising stars It’s too early to say how big ivonescimab could become in the cancer space, Dara Azar, associate vice president of Biotech Equity Research at Stifel, told BioSpace in an email interview, “but it looks like AstraZeneca didn’t want to wait.” Most recently, the pharma and partner Daiichi Sankyo inked a clinical trial collaboration to evaluate their TROP2-targeting antibody-drug conjugate (ADC) Datroway alongside ivonescimab in multiple tumor types. The collaboration will kick off with a late-stage study in first-line triple-negative breast cancer, though the companies haven’t specified a start date. And just days before the Datroway deal, AstraZeneca announced a separate clinical trial collaboration with Summit that will combine ivonescimab with its anti-CLDN18.2 ADC sonesitatug vedotin (sone-ve). The agreement focuses on gastrointestinal cancers, with studies set to begin “imminently,” the pharma said. Part of why AstraZeneca has pushed so hard with ivonescimab combo deals, Azar said, could be because many of its peers were already in the PD-1xVEGF race. Merck in November 2024 paid $588 million upfront and put an additional $2.7 billion on the line to exclusively license LaNova Medicines’ PD-1xVEGF bispecific LM-299. Pfizer, meanwhile, has also started building out its PD-1xVEGF pipeline, betting up to $6 billion in May 2025 to advance 3SBio’s SSGJ-707, now named PF-08634404 and in multiple clinical trials across urothelial carcinoma, NSCLC and renal cell carcinoma, among other cancer types. Already having a PD-1xVEGF doesn’t mean these pharmas aren’t also considering an ivonescimab combo. Three months before inking the 3SBio pact, Pfizer entered into a clinical trial collaboration with Summit to test ivonescimab with “several” of its ADCs for various solid tumor indications. Pfizer is putting forward its vedotin ADCs, most of which it obtained in the $43 billion acquisition of Seagen in 2023. This class includes its FDA-approved Padcev, indicated for urothelial cancer , and sigvotatug vedotin, in Phase 3 development for NSCLC. Ivonescimab’s appeal also extends beyond Big Pharma. In June 2025, Revolution Medicines—which recently secured FDA approval for its pancreatic cancer drug Rasonque— offered its array of RAS(ON) inhibitors, including Rasonque, as potential combination partners for ivonescimab. This clinical trial tie-up also includes the investigational G12D-selective and G12C-selective inhibitors zoldonrasib and elironrasib, respectively. Cancer RevMed could become ‘next oncology titan’ with Rasonque nod A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities. August 27, 2026 · 2 min read · Tristan Manalac Read more Even more such deals are on the way, Gancarz told BioSpace , though he declined to provide specific details, as these potential partnerships are still under discussion. The next Keytruda? While the influx of interest in ivonescimab bodes well for the up-and-comer, the therapy still has a long way to go to dethrone Keytruda. “Keytruda is the most successful cancer drug of all time, with the drug now approved to treat over 40 cancers, and global revenue topping $31bn in 2025,” Mizuho’s Suvannavejh told BioSpace . Earnings Keytruda Hangs On to Best Seller Crown as GLP-1s Gain Ground Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s. March 4, 2026 · 9 min read · Tristan Manalac Read more But ivonescimab earned its “Keytruda killer” nickname for a reason. While an overall survival miss in a global Phase 3 study in May 2025 dampened sentiment surrounding the bispecific’s competitive value, many still believe that ivonescimab will ultimately be a more effective treatment than Merck’s. “Investors expect this drug to ultimately be proven as the better checkpoint inhibitor,” Stifel’s Azar told BioSpace . Ivonescimab is currently under FDA review as a second-line treatment for patients with advanced non-squamous NSCLC, with a decision expected Nov. 14 . Looking at ivonescimab’s body of data so far, Azar doesn’t expect the drug to run into any major regulatory issues. AstraZeneca is a bit more reserved when it comes to ivonescimab. “It is important to be balanced about the evidence,” the spokesperson said. “Much of the positive data to date comes from China-only trials, and we recognize that single-region data have more limited relevance to populations outside China.” Indeed, ivonescimab’s current application is backed by the Phase 3 HARMONi trial, which hinted at slight differences in the drug’s efficacy between Asian and Western patients. Summit did not provide statistical analyses for the survival benefit seen in HARMONi, however. The AstraZeneca spokesperson said ivonescimab will need to show that it can significantly improve overall survival in global patient populations to credibly support an approval bid outside of China. More Western data should be coming soon. Summit is anticipating final progression-free survival (PFS) data from the Phase 3 multiregional HARMONi-3 study testing ivonescimab versus Keytruda as a frontline treatment option for NSCLC before the end of the year. “All eyes are focused on the announcement of Phase 3 HARMONi-3 study data,” Suvannavejh said. “If the data do pan out,” he continued, “then simply put, ivonescimab has the potential to replace Keytruda as the next major backbone of treatment in cancer—and in turn, to become the next best-selling oncology drug of all time.” Lung cancer Summit shares descend as PD-1/VEGF asset misses early survival mark Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders. May 4, 2026 · 2 min read · Tristan Manalac Read more

Phase 3AcquisitionDrug Approval

28 Sep 2026

·www.pfizer.com

Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF’4404) NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer. “At Pfizer Oncology, we're focused on improving outcomes for people living with cancer. That means continuing to raise the standard of care today while pursuing the breakthroughs that will shape the future of oncology. The data we're presenting at ESMO reflect that focus, strengthening the evidence behind medicines such as PADCEV and TALZENNA, while advancing promising investigational candidates including atirmociclib and tivunatamig. By building on our leadership in breast, genitourinary, and lung cancers, we're working to bring meaningful progress to patients today and for years to come.” - Jeff Legos, Chief Oncology Officer, Pfizer Key Highlights of Pfizer’s Presence at ESMO 2026 Guiding the Next Wave of Oncology Innovation Phase 2 randomized results from the FOURLIGHT-1 study of atirmociclib, a highly selective cyclin-dependent kinase (CDK) 4 inhibitor, plus fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC) who had received prior CDK 4/6 inhibitor-based treatment. These results further support atirmociclib as a potential first-in-class cell cycle inhibitor backbone for HR+, HER2- MBC and Pfizer’s development strategy in earlier lines of therapy. A Phase 3 study in frontline MBC is ongoing and an additional Phase 3 study in early breast cancer is planned to evaluate atirmociclib in combination with giredestrant, an investigational oral selective oestrogen receptor degrader under development by Roche. (Presentation #1842O) Late-breaking overall survival (OS) and progression-free survival (PFS) results from the Phase 3 SigVie-002 study evaluating sigvotatug vedotin (SV), an investigational integrin β6 (IB6)-directed antibody-drug conjugate (ADC), as monotherapy in previously treated non-squamous non-small cell lung cancer (NSCLC). The findings will provide additional insight into previously announced topline results and inform the continued development of SV in earlier treatment settings, including an ongoing Phase 3 trial evaluating SV in combination with pembrolizumab in first-line advanced NSCLC and additional novel combinations under evaluation. (Presentation #LBA68) Updated Phase 2 data for tivunatamig (PF-08634404, PF’4404), a novel bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in first-line PD-L1-expressing NSCLC. Tivunatamig is being developed as a potential best-in-class backbone therapy designed to combine two validated and complementary pathways in a single agent across tumor types, including ongoing pivotal studies in first-line NSCLC, first-line metastatic colorectal cancer, and advanced/recurrent endometrial cancer. Additional Phase 3 combination studies are planned, including with PADCEV ®(enfortumab vedotin-ejfv) in metastatic urothelial cancer. (Presentation #2660P) Expanding Evidence Across the Portfolio Updated exploratory analyses from the Phase 3 EV-302 trial evaluating outcomes with PADCEV plus pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), including among older patients, patients with comorbidities, and subgroups defined by disease-related characteristics. The findings further strengthen confidence in the regimen as a first-line foundation of care in la/mUC across clinically relevant populations. (Presentations #4760P and #4761P) Results from STARBOARD, a non-registrational Phase 3 trial evaluating an investigational triplet combination regimen of BRAFTOVI ®(encorafenib) and MEKTOVI ®(binimetinib) with pembrolizumab (KEYTRUDA ®) in first-line BRAF V600-mutant advanced melanoma. These findings contribute important evidence to an evolving treatment landscape. (Presentation #2071O) Deepening Understanding of Treatment Outcomes and Patient Experience Patient-reported outcomes and a safety analysis from the Phase 3 TALAPRO-3 study further supporting TALZENNA ®(talazoparib) plus XTANDI ® (enzalutamide) as a potential treatment option for men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC; also known as metastatic APMN/S prostate cancer). A supplemental New Drug Application (sNDA) for TALZENNA plus XTANDI in mAPMN/S is currently under Priority Review by the U.S. Food and Drug Administration (FDA). (Presentations #2222RO and #2231P) An ad-hoc analysis from the Phase 3 EV-303 trial (also known as KEYNOTE-905) and circulating tumor DNA (ctDNA) and health-related quality of life analyses from the Phase 3 EV-304 (KEYNOTE-B15) trial. These analyses provide important biological and patient-centered context to previously reported survival data and further support perioperative PADCEV plus pembrolizumab as a new potential standard of care in muscle-invasive bladder cancer (MIBC). (Presentations #4733O, #4734O and #4738RO) ESMO Presence Reinforces Pfizer Oncology's Strategy to Advance Standards of Care and Deliver Next-Generation Breakthroughs As cancer remains the second-leading cause of death worldwide, Pfizer is focused on generating the evidence needed to bring treatment breakthroughs to as many patients as possible. Our data at ESMO reflect that strategy, concentrating innovation in disease areas with the greatest opportunity to impact patients globally. Highlights include emerging data from late-stage investigational programs advancing next-generation treatments, new analyses supporting established medicines as standards of care, and insights that deepen understanding of patient experience to better inform clinical decisions. Detailed Presentation Information Information on significant Pfizer and partner-sponsored abstracts, including date and time of presentation, follows in the chart below. A complete list of Pfizer and partner-sponsored abstracts and presentations is available here. Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (aPLS) for company-sponsored research being presented at ESMO, which are written in non-technical language. Those interested in learning more can visit www.Pfizer.com/apls to access the summaries. Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV® and KEYTRUDA® in patients with previously untreated metastatic urothelial cancer and MIBC regardless of cisplatin eligibility. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). XTANDI® is jointly developed and commercialized by Pfizer and Astellas in the United States. Prescribing Information for Pfizer Medicines Please see full Prescribing Information for BRAFTOVI® (encorafenib) and full Prescribing Information for MEKTOVI® (binimetinib). Please see full Prescribing Information for PADCEV® (enfortumab vedotin-ejfv). Please see full Prescribing Information for TALZENNA® (talazoparib). Please see full Prescribing Information for XTANDI® (enzalutamide). About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including immuno-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and lung cancers. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website atwww.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at www.facebook.com/Pfizer/. Disclosure notice The information contained in this release is as of September 28, 2026. The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer Oncology and Pfizer’s oncology portfolio of marketed and investigational therapies, including combinations, and including their potential benefits; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications or combinations, including expected clinical trial protocols, the potential and timing for the initiation and progress of clinical trials and data read-outs from trials; the timing and potential for the submission of applications for and receipt of regulatory approvals; the timing and potential for product launches and commercialization; expected breakthrough, best- or first-in-class or blockbuster status or expected market entry of our medicines; potential patients reached; the regulatory landscape; the competitive landscape; and other statements about our business, operations and financial results that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s oncology portfolio; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Pfizer Media Contact: PfizerMediaRelations@Pfizer.com Pfizer Investor Relations: IR@pfizer.com Source: Pfizer Inc.

Phase 3Phase 2ASCOPriority Review

28 Sep 2026

·www.biospace.com

Pfizer Advances Today’s Cancer Care and Tomorrow’s Potential Breakthroughs at ESMO

Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF’4404) NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer. “At Pfizer Oncology, we're focused on improving outcomes for people living with cancer. That means continuing to raise the standard of care today while pursuing the breakthroughs that will shape the future of oncology. The data we're presenting at ESMO reflect that focus, strengthening the evidence behind medicines such as PADCEV and TALZENNA, while advancing promising investigational candidates including atirmociclib and tivunatamig. By building on our leadership in breast, genitourinary, and lung cancers, we're working to bring meaningful progress to patients today and for years to come.” - Jeff Legos, Chief Oncology Officer, Pfizer Key Highlights of Pfizer’s Presence at ESMO 2026 Guiding the Next Wave of Oncology Innovation Phase 2 randomized results from the FOURLIGHT-1 study of atirmociclib, a highly selective cyclin-dependent kinase (CDK) 4 inhibitor, plus fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC) who had received prior CDK 4/6 inhibitor-based treatment. These results further support atirmociclib as a potential first-in-class cell cycle inhibitor backbone for HR+, HER2- MBC and Pfizer’s development strategy in earlier lines of therapy. A Phase 3 study in frontline MBC is ongoing and an additional Phase 3 study in early breast cancer is planned to evaluate atirmociclib in combination with giredestrant, an investigational oral selective oestrogen receptor degrader under development by Roche. (Presentation #1842O) Late-breaking overall survival (OS) and progression-free survival (PFS) results from the Phase 3 SigVie-002 study evaluating sigvotatug vedotin (SV), an investigational integrin β6 (IB6)-directed antibody-drug conjugate (ADC), as monotherapy in previously treated non-squamous non-small cell lung cancer (NSCLC). The findings will provide additional insight into previously announced topline results and inform the continued development of SV in earlier treatment settings, including an ongoing Phase 3 trial evaluating SV in combination with pembrolizumab in first-line advanced NSCLC and additional novel combinations under evaluation. (Presentation #LBA68) Updated Phase 2 data for tivunatamig (PF-08634404, PF’4404), a novel bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in first-line PD-L1-expressing NSCLC. Tivunatamig is being developed as a potential best-in-class backbone therapy designed to combine two validated and complementary pathways in a single agent across tumor types, including ongoing pivotal studies in first-line NSCLC, first-line metastatic colorectal cancer, and advanced/recurrent endometrial cancer. Additional Phase 3 combination studies are planned, including with PADCEV ® (enfortumab vedotin-ejfv) in metastatic urothelial cancer. (Presentation #2660P) Expanding Evidence Across the Portfolio Updated exploratory analyses from the Phase 3 EV-302 trial evaluating outcomes with PADCEV plus pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), including among older patients, patients with comorbidities, and subgroups defined by disease-related characteristics. The findings further strengthen confidence in the regimen as a first-line foundation of care in la/mUC across clinically relevant populations. (Presentations #4760P and #4761P) Results from STARBOARD, a non-registrational Phase 3 trial evaluating an investigational triplet combination regimen of BRAFTOVI ® (encorafenib) and MEKTOVI ® (binimetinib) with pembrolizumab (KEYTRUDA ® ) in first-line BRAF V600-mutant advanced melanoma. These findings contribute important evidence to an evolving treatment landscape. (Presentation #2071O) Deepening Understanding of Treatment Outcomes and Patient Experience Patient-reported outcomes and a safety analysis from the Phase 3 TALAPRO-3 study further supporting TALZENNA ® (talazoparib) plus XTANDI ® (enzalutamide) as a potential treatment option for men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC; also known as metastatic APMN/S prostate cancer). A supplemental New Drug Application (sNDA) for TALZENNA plus XTANDI in mAPMN/S is currently under Priority Review by the U.S. Food and Drug Administration (FDA). (Presentations #2222RO and #2231P) An ad-hoc analysis from the Phase 3 EV-303 trial (also known as KEYNOTE-905) and circulating tumor DNA (ctDNA) and health-related quality of life analyses from the Phase 3 EV-304 (KEYNOTE-B15) trial. These analyses provide important biological and patient-centered context to previously reported survival data and further support perioperative PADCEV plus pembrolizumab as a new potential standard of care in muscle-invasive bladder cancer (MIBC). (Presentations #4733O, #4734O and #4738RO) ESMO Presence Reinforces Pfizer Oncology's Strategy to Advance Standards of Care and Deliver Next-Generation Breakthroughs As cancer remains the second-leading cause of death worldwide, Pfizer is focused on generating the evidence needed to bring treatment breakthroughs to as many patients as possible. Our data at ESMO reflect that strategy, concentrating innovation in disease areas with the greatest opportunity to impact patients globally. Highlights include emerging data from late-stage investigational programs advancing next-generation treatments, new analyses supporting established medicines as standards of care, and insights that deepen understanding of patient experience to better inform clinical decisions. Detailed Presentation Information Information on significant Pfizer and partner-sponsored abstracts, including date and time of presentation, follows in the chart below. A complete list of Pfizer and partner-sponsored abstracts and presentations is available here . LUNG CANCER Proffered Paper 1 LBA68 October 25, 2026 10:15–11:45 CET Phase 3 study of sigvotatug vedotin (SV) vs docetaxel in previously treated non-squamous non-small cell lung cancer (NSCLC) [ LBA ] Peters et al Poster Presentation 2660P October 26, 2026 12:00–12:45 CET Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results [ 3SBio ] Wu et al BREAST CANCER Proffered Paper Session 1842O October 24, 2026 08:30–10:00 CET Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK 4/6 inhibitor (CDK 4/6i) in a randomized phase 2 study (FOURLIGHT-1) Giordano et al Proffered Paper Session 1766RO October 24, 2026 10:15–11:45 CET Health-related quality of life from HER2CLIMB-05: A Phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC Dieras et al GENITOURINARY CANCERS: BLADDER AND PROSTATE Rapid Oral Session 2219RO October 23, 2026 13:30–15:00 CET Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC) Azad et al Rapid Oral Session 2222RO October 23, 2026 13:30–15:00 CET Patient-reported outcomes (PROs) in men with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from the Phase 3 TALAPRO-3 study Azad et al Proffered Paper Session 4733O October 23, 2026 13:30–15:00 CET Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: Ad hoc analysis from KEYNOTE-905 [ MSD led ] Ullén et al Proffered Paper Session 4734O October 23, 2026 13:30–15:00 CET ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin [ MSD led ] Chatzkel et al Poster Presentation 2296P October 23, 2026, 15:15-16:00 CET Safety and efficacy of mevrometostat monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) J. Carles Galceran et al Poster Presentation 2231P October 23, 2026 15:15–16:00 CET Talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations: Safety analyses from the Phase 3 TALAPRO-3 study Mateo et al Poster Presentation 4761P October 23, 2026 15:15–16:00 CET Enfortumab vedotin plus pembrolizumab (EV+P) for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Updated exploratory analysis of EV-302 in older patients (pts) and those with comorbidities Sridhar et al Poster Presentation 4760P October 23, 2026 15:15–16:00 CET Enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Exploratory analyses based on disease-related characteristics from EV-302 Bedke et al Proffered Paper Session 4738RO October 24, 2026 10:15–11:45 CET Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEYNOTE-B15 study [ MSD led ] Gómez De Liaño et al MELANOMA Proffered Paper Session 2071O October 23, 2026 16:15–17:45 CET STARBOARD Phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (PBO) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma Schadendorf et al Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (aPLS) for company-sponsored research being presented at ESMO, which are written in non-technical language. Those interested in learning more can visit to access the summaries. Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV ® and KEYTRUDA ® in patients with previously untreated metastatic urothelial cancer and MIBC regardless of cisplatin eligibility. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). XTANDI ® is jointly developed and commercialized by Pfizer and Astellas in the United States. Prescribing Information for Pfizer Medicines Please see full Prescribing Information for BRAFTOVI ® (encorafenib) and full Prescribing Information for MEKTOVI ® (binimetinib). Please see full Prescribing Information for PADCEV ® (enfortumab vedotin-ejfv). Please see full Prescribing Information for TALZENNA ® (talazoparib). Please see full Prescribing Information for XTANDI ® (enzalutamide). About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including immuno-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and lung cancers. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at . In addition, to learn more, please visit us on and follow us on X at @Pfizer and @Pfizer_News , LinkedIn , YouTube and like us on Facebook at . Disclosure notice The information contained in this release is as of September 28, 2026. The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer Oncology and Pfizer’s oncology portfolio of marketed and investigational therapies, including combinations, and including their potential benefits; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications or combinations, including expected clinical trial protocols, the potential and timing for the initiation and progress of clinical trials and data read-outs from trials; the timing and potential for the submission of applications for and receipt of regulatory approvals; the timing and potential for product launches and commercialization; expected breakthrough, best- or first-in-class or blockbuster status or expected market entry of our medicines; potential patients reached; the regulatory landscape; the competitive landscape; and other statements about our business, operations and financial results that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s oncology portfolio; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and . Contacts Pfizer Media Contact: PfizerMediaRelations@Pfizer.com Pfizer Investor Relations: IR@pfizer.com

Phase 3Phase 2Clinical ResultASCOPriority Review

100 Deals associated with Sigvotatug vedotin

External Link

KEGG	Wiki	ATC	Drug Bank
D13007	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Argentina	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Australia	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Austria	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Belgium	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Brazil	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Bulgaria	Pfizer Inc.	23 Jul 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Canada	Pfizer Inc.	23 Jul 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06758401 (SigVie-003, ASCO2026)	Phase 3	PD-L1 positive Non-Small Cell Lung Cancer First line PD-L1 TPS ≥50%	714	Sigvotatug vedotin+pembrolizumab (NSCLC with PD-L1 TPS ≥50%)	ctzmpdpwjf(hqkqbscbpd) = nxxcioyhci sgatvnvepr (hzjmypcyjs, 69.1 - 80.8) View more	Positive	29 May 2026
				Pembrolizumab (NSCLC with PD-L1 TPS ≥50%)	anutvwzbtz(fowgxktdkm) = axpyhimpcz gnrjicihub (angdfhczey, 5.3 - 6.4) View more
NCT06758401 (Sigvie-003, Pubmed \| Future Oncol)	Phase 3	PD-L1 positive Non-Small Cell Lung Cancer First line PD-L1 tumor proportion score ≥50%	714	Sigvotatug vedotin plus pembrolizumab	itxohauvhd(umvwelabau) = iadmawmnuo vvmziyilbm (etucrsnitw, 18.4 - NR) View more	Positive	20 Dec 2025
				Pembrolizumab	vchzevhwsm(cfxedjarsf) = oodwwonpjx ewosksoars (wzbdhbzkhl ) View more
NCT04389632 (SGNB6A-001, ASCO2025)	Phase 1	Pancreatic adenocarcinoma \| Ovarian Cancer \| Adenocarcinoma of Esophagus ... PD-L1 TPS \| PD-L1 CPS View more	31	Sigvotatug vedotin (SV) 1.8 mg/kg	bveemvmqix(wyhpauqreq) = dqpinwhevl hqauxfdnxe (ladkquehqc ) View more	Positive	30 May 2025
NCT04389632 (SGNB6A-001, ASCO2024) Manual	Phase 1	Non-Small Cell Lung Cancer Integrin beta-6 (IB6)	113	Sigvotatug vedotin	rmgsgsqrpt(iwgxbcyuhe) = rbjlpsqbtk dblkvklhay (sabzrwudcx, 12.6 - 28.0) View more	Positive	24 May 2024
				Sigvotatug vedotin (1.8 mg/kg AiBW)	rmgsgsqrpt(iwgxbcyuhe) = ukmwiaraav dblkvklhay (sabzrwudcx, 8.6 - 42.3) View more
NCT04389632 (SGNB6A-001, ASCO 12023 \| ASCO 22023) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	148	SGN B6A	dsjrpskykz(vmwyrzrkmi) = mwahqlpisy kizblmkfis (sgozytvzog ) View more	Positive	26 May 2023
				SGN B6A (NSCLC)	ypoemxkeze(vafzrkyogg) = hhjzbduwna gnyvicmmvh (phfknungtj ) View more
NCT04389632 (SGNB6A-001, SITC2022) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	48	SGN-B6A (Q1W)	izunufqrdr(ltfpypfggt) = jzedxxtyld tukhnzoknq (kiqwerwccg )	Positive	01 Nov 2022
				SGN-B6A (2Q3W)	izunufqrdr(ltfpypfggt) = twbdmkdpxp tukhnzoknq (kiqwerwccg )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis